statistiche ricercatore

CANDUCCI, FILIPPO

Distribuzione geografica

Continente	#
NA - Nord America	6.393
EU - Europa	3.065
AS - Asia	1.892
SA - Sud America	125
Continente sconosciuto - Info sul continente non disponibili	30
AF - Africa	21
OC - Oceania	4
Totale	11.530

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	6.248
IT - Italia	1.680
SG - Singapore	621
UA - Ucraina	504
VN - Vietnam	327
TR - Turchia	317
CN - Cina	308
SE - Svezia	249
HK - Hong Kong	217
FI - Finlandia	134
DE - Germania	114
CA - Canada	110
BR - Brasile	97
FR - Francia	97
IE - Irlanda	92
GB - Regno Unito	83
RU - Federazione Russa	62
JP - Giappone	24
IN - India	23
MX - Messico	21
BD - Bangladesh	12
AR - Argentina	11
ES - Italia	10
BE - Belgio	9
EU - Europa	9
IQ - Iraq	9
NL - Olanda	9
PL - Polonia	8
ZA - Sudafrica	8
EC - Ecuador	6
ID - Indonesia	6
AT - Austria	5
LT - Lituania	4
TT - Trinidad e Tobago	4
VE - Venezuela	4
CL - Cile	3
EG - Egitto	3
IL - Israele	3
KE - Kenya	3
AE - Emirati Arabi Uniti	2
AU - Australia	2
BZ - Belize	2
DO - Repubblica Dominicana	2
DZ - Algeria	2
ET - Etiopia	2
KZ - Kazakistan	2
LB - Libano	2
MD - Moldavia	2
MY - Malesia	2
NG - Nigeria	2
NI - Nicaragua	2
NP - Nepal	2
NZ - Nuova Zelanda	2
PE - Perù	2
PK - Pakistan	2
SA - Arabia Saudita	2
BB - Barbados	1
BH - Bahrain	1
BY - Bielorussia	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
GY - Guiana	1
HN - Honduras	1
JM - Giamaica	1
JO - Giordania	1
KG - Kirghizistan	1
KR - Corea	1
KW - Kuwait	1
MA - Marocco	1
NO - Norvegia	1
OM - Oman	1
PH - Filippine	1
PS - Palestinian Territory	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	11.509

Salva come PNG Salva come JPEG

Città	#
Milan	1.282
Fairfield	841
Woodbridge	508
Ashburn	502
Jacksonville	429
Houston	388
San Jose	385
Singapore	364
Chandler	350
Ann Arbor	313
Seattle	302
Cambridge	298
Wilmington	275
Hong Kong	213
Nyköping	163
Princeton	144
Izmir	141
Dearborn	137
Dallas	129
Boardman	115
The Dalles	110
Toronto	95
Council Bluffs	93
Dong Ket	93
Dublin	89
Beijing	84
Rome	73
Lauterbourg	62
Como	54
Hanoi	46
San Diego	46
Ho Chi Minh City	41
New York	25
Los Angeles	24
Santa Clara	24
Tokyo	23
Chicago	21
London	20
Nanjing	20
Ogden	20
Kunming	16
Hefei	15
Mexico City	14
Orem	14
Atlanta	12
São Paulo	12
Haiphong	11
Da Nang	10
Washington	10
Brussels	9
Munich	9
Chengdu	8
Chennai	8
Columbus	8
Denver	8
Guangzhou	8
Montreal	8
Phoenix	8
Verona	8
Warsaw	8
Brooklyn	7
Helsinki	7
Jinan	7
Mumbai	7
Norwalk	7
Nuremberg	7
Nanchang	6
Ponte Lambro	6
Baghdad	5
Hounslow	5
Johannesburg	5
Poplar	5
Guayaquil	4
Kilburn	4
Las Vegas	4
Redmond	4
Salt Lake City	4
Wuhan	4
Amsterdam	3
Boston	3
Can Tho	3
Curitiba	3
Elk Grove Village	3
Fuzhou	3
Huzhou	3
Nairobi	3
Phú Nhuận	3
Redwood City	3
Rio de Janeiro	3
San Francisco	3
Secaucus	3
Thủ Đức	3
Tübingen	3
Vienna	3
Abuja	2
Addis Ababa	2
Alexandria	2
Anápolis	2
Aparecida de Goiânia	2
Auckland	2
Totale	8.704

Salva come PNG Salva come JPEG

Nome	#
Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota	225
Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation	219
The Microbiome of the Prostate Tumor Microenvironment	216
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.	209
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity	208
Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation	205
Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients.	201
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules	198
Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques.	196
Coronaviridae and SARS-associated coronavirus strain HSR1.	195
The interplay of extracellular matrix and microbiome in urothelial bladder cancer	184
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.	183
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.	182
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.	182
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.	181
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.	179
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL-authors' response	179
Immunological recovery after 24 weeks of antiretroviral therapy in patients with x4 virus during primary hiv infection	178
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up	177
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.	177
Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding	176
Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV).	173
Efficacy of a multistep strategy for Helicobacter pylori eradication.	172
Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients.	171
Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection.	171
2-aminothiazolones as anti-HIV agents which act as gp120-CD4 Inhibitors	170
Helicobacter pylori treatment: a role for probiotics?	168
Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient.	167
Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction.	166
Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment	166
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.	165
Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction.	162
GB virus C and survival in persons with HIV infection	161
Probiotics and Helicobacter pylori eradication.	160
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.	159
Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach	159
Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease.	158
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression	158
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.	158
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.	157
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.	156
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family	155
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein.	155
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.	154
Pregnancy and H1N1 infection.	154
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir	154
Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	153
The role of infections and coinfections with newly identified and emerging respiratory viruses in children.	153
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients.	153
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.	152
Comparison of the artus HIV-1 QS-RGQ and VERSANT HIV-1 RNA 1.0 assays for quantitative detection of human immunodeficiency virus type 1 in plasma samples	150
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.	149
IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation	149
Infection and coinfection of human rhinovirus C in stem cell transplant recipients.	148
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.	148
Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.	144
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.	143
A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments.	142
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.	138
Characterization of GBV-C infection in HIV-1 infected patients.	136
Quantitative HIV-1 proviral DNA detection: a multicentre analysis.	132
Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.	120
Phage display for the production of human monoclonal antibodies against human pathogens.	113
Humoral immune response against hepatitis C virus.	111
Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV).	106
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.	106
Helicobacter pylori: a culprit in extraintestinal diseases?	102
Phylogenetic internal control for HIV-1 genotypic antiretroviral testing.	102
Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation	101
Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.	99
Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	99
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.	96
TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis	86
Totale	11.530

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	45.360
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	45.360

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	574	0	141	5	53	8	21	41	42	33	82	66	82
2022/2023	990	79	6	48	114	111	245	1	135	184	26	14	27
2023/2024	1.794	311	330	304	338	353	83	5	13	36	4	0	17
2024/2025	701	1	1	151	5	6	77	65	18	25	54	64	234
2025/2026	2.139	187	133	96	248	211	109	446	117	299	157	101	35
2026/2027	117	42	75	0	0	0	0	0	0	0	0	0	0
Totale													11.530